Expression of Glucose Transporter-1, Hexokinase-II, Proliferating Cell Nuclear Antigen and Survival of Patients with Pancreatic Cancer

REFERENCES

• Sarmiento J. M., Sarr M. G. Staging strategies for pancreatic adenocarcinoma: what the surgeon really wants to know. Curr. Gastroenterol. Rep. 2003; 5: 17–24
   Google Scholar
• Yeo C. J., Cameron J. L. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch. Surg. 1998; 393: 129–133
   Google Scholar
• Lillemoe K. D., Pitt H. A. Palliation. surgical and otherwise. Cancer 1996; 78: 605–614
   Google Scholar
• Nakamoto Y., Higashi T., Sakahara H., Tamaki N., Kogire M., et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000; 89: 2547–2554
   PubMed Web of Science ®Google Scholar
• Nakata B., Nishimura S., Ishikawa T., Ohira M., Nishino H., et al. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int. J. Oncol. 2001; 19: 53–58
   PubMed Web of Science ®Google Scholar
• Zimny M., Fass J., Bares R., Cremerius U., Sabri O., et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand. J. Gastroenterol. 2000; 35: 883–888
   PubMed Web of Science ®Google Scholar
• UICC. TNM Classification of Malignant Tumors, 6th edition, L. H. Sobin, Ch. Wittekind. Wiley-Liss, New York 2002
   Google Scholar
• Bramhall S. R., Allum W. H., Jones A. G., Allwood A., Cummins C., Neoptolemos J. P. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br. J. Surg. 1995; 82: 111–115
   PubMed Web of Science ®Google Scholar
• Ghaneh P., Kawesha A., Evans J. D., Neoptolemos J. P. Molecular prognostic markers in pancreatic cancer. J. Hepatobiliary Pancreat. Surg. 2002; 9–11
   Google Scholar
• Lim J. E., Chien M. W., Earle C. C. Prognostic factors following curative resection for pancreatic adenocarcinoma. A population-based, linked databased analysis of 396 patients. Ann. Surg. 2003; 237: 74–85
   PubMed Web of Science ®Google Scholar
• Buck A., Schirrmeister H., Kuhn T., Shen C., Kalker T., et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur. J. Nucl. Med. Mol. Imaging 2002; 29: 1317–1323
   PubMed Web of Science ®Google Scholar
• Halfpenny W., Hain S. F., Biassoni L., Maisey M. N., Sherman J. A., McGurk M. FDG-PETA possible prognostic factor in head and neck cancer. Br. J. Cancer 2002; 86: 512–516
   PubMed Web of Science ®Google Scholar
• Zimny M., Fass J., Bares R., Cremerius U., Sabri O., et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand. J. Gastroenterol. 2003; 35: 883–8883
   Google Scholar
• Sperti C., Pasquali C., Chierichetti F., Ferronato A., Decet G., Pedrazzoli S. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J. Gastrointest. Surg. 2003; 7: 953–960
   PubMed Web of Science ®Google Scholar
• Lyshchik A., Higashi T., Nakamoto Y., Fujimoto K., Doi R., Imamura M., Saga T. Dual-phase (18)F-fluoro-2-deoxy-D: -glucose positron emission tomography as a prognostic parameter in patients with pancreaticcancer. Eur. J. Nucl. Med. Mol. Imaging 2005; 32: 389–397
   PubMed Web of Science ®Google Scholar
• Burant C. F., Sivitz W. I., Fukumoto H., Kayano T., Nagamatsu S., et al. Mammalian glucose transporters; structure and molecular regulation. Recent Prog. Horm. Res. 1991; 47: 349–388
   PubMedGoogle Scholar
• Haber R. S., Rathan A., Weiser K. R., Pritsker A., Itzkowitz S. H., et al. Glut1 glucose transporter expression in colorectal carcinoma. Cancer 1998; 83: 34–40
   PubMed Web of Science ®Google Scholar
• Younes M., Brown R. W., Stephenson M., Gondo M., Cagle P. T. Overexpression of Glut1 and Glut3 in state 1 non-small cell lung carcinoma is associated with poor survival. Cancer 1997; 80: 1046–1051
   PubMed Web of Science ®Google Scholar
• Airley R., Loncaster J., Davidson S., Bromley M., Roberts S., et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin. Cancer Res. 2001; 7: 928–934
   PubMed Web of Science ®Google Scholar
• Higashi T., Tamaki N., Honda T., Torizuka T., Kimura T., et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J. Nucl. Med. 1997; 38: 1337–1344
   PubMed Web of Science ®Google Scholar
• Higashi T., Tamaki N., Torizuka T., Nakamoto Y., Sakahara H., et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J. Med. 1998; 39: 1727–1735
   Google Scholar
• Smith T. A. FDG uptake, tumor characteristics and response to therapy: a review. Nucl. Med. Commun. 1998; 19: 97–105
   PubMed Web of Science ®Google Scholar
• Higashi T., Saga T., Nakamoto Y., Ishimori T., Mamede M. H., et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J. Nucl. Med. 2002; 43: 173–80
   PubMed Web of Science ®Google Scholar
• Bravo R., Rainer F., Blundell P. A., Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase. Nature 1987; 326: 515–517
   PubMed Web of Science ®Google Scholar
• Theunissen P. H., Leers M. P., Bollen E. C. PCNA expression in formalin-fixed tissue of NSCLC. Histopathology 1992; 20: 251–255
   PubMed Web of Science ®Google Scholar
• Oyama T., Mitsudomi T., Mizoue T., Ohgami A., Osaki T., Nakanishi R., Yasumoto K. Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer region in predicting shortened survival of patients with non-small cell lung cancer. Surg. Oncol. 1995; 83–89
   PubMed Web of Science ®Google Scholar
• Fuji M., Motoi M., Saeki H., et al. Prognostic significance of proliferating cell nuclear antigen (PCNA) expresion in nonsmall cell lung cancer. Acta Med. Okayama 1993; 47: 103–103
   PubMed Web of Science ®Google Scholar
• Esposito V., Baldi A., De Lucca A., et al. Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum. Pathol. 1997; 28: 233–237
   PubMed Web of Science ®Google Scholar
• Jacob R., Welkoborsky H. J., Mann W. J., Jauch M., Amedee R. [Fluorine-[8]fluorodeoxyglucose positron emission tomography. DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck. ORL J. Otorhinolaryngol. Relat. Spec. 2001; 63: 307–313
   PubMed Web of Science ®Google Scholar
• Higashi K., Ueda Y., Yagishita M., Arisaka Y., Sakurai A., et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J. Nucl. Med. 2000; 41: 85–92
   PubMed Web of Science ®Google Scholar